← FDA DRUG APPROVALS

FDA ANDA · ANDA212346

POTASSIUM CHLORIDE

potassium chloride, dextrose monohydrate

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA212346
TYPE
ANDA
ORIGINAL APPROVAL
2020-09-10
LATEST ACTION
2020-09-10
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%Prescription
DEXTROSE 5GM/100ML, POTASSIUM CHLORIDE 75MG/100ML · INJECTABLE · INJECTION
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%Prescription
DEXTROSE 5GM/100ML, POTASSIUM CHLORIDE 150MG/100ML · INJECTABLE · INJECTION

Approval history

2020-09-10UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →